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ABSTRACT
Kinases such as MEK are attractive targets for novel therapy in cancer, including
acute myeloid leukaemia (AML). Acquired and inherent resistance to kinase inhibitors,
however, is becoming an increasingly important challenge for the clinical success
of such therapeutics, and often arises from mutations in the drug-binding domain
of the target kinase. To identify possible causes of resistance to MEK inhibition, we
generated a model of resistance by long-term treatment of AML cells with AZD6244
(selumetinib). Remarkably, resistance to MEK inhibition was due to acquired PTEN
haploinsufficiency, rather than mutation of MEK. Resistance via this mechanism was
confirmed using CRISPR/Cas9 technology targeting exon 5 of PTEN. While PTEN loss
has been previously implicated in resistance to a number of other therapeutic agents,
this is the first time that it has been shown directly and in AML.

INTRODUCTION

arabinoside, Ara-C), etoposide and anthracyclines [6].
For relapsed patients, most therapeutic regimens include
further cytarabine in combination with other agents [7].
The effectiveness of chemotherapy is limited by not only
acute toxicity, but also late effects such as an increased risk
of secondary malignancy and cardiotoxicity [8, 9]. These
chemotherapy-associated side effects are of particular
concern in children given that treatment occurs during
growth and development. Therefore, there is a desperate
need for more efficacious, yet less toxic, therapeutic
strategies to improve outcomes for pediatric AML patients.
Substantial evidence supports an essential role of
Ras/Raf/MEK/ERK1/2 kinases in tumourigenesis [10].
Constitutive activity of the Ras/Raf/MEK/ERK1/2 signaling
cascade has been reported in a wide variety of liquid and

Pediatric acute myeloid leukemia (AML) causes
a disproportionate number of childhood cancer deaths
[1, 2]. The peak incidence of childhood AML occurs in
children under 4 years (1.1 per 100,000; 1982–2007)
[2, 3]. The event-free survival for childhood AML is only
50 to 60% despite complete remissions being achieved
in approximately 90% of children with front-line therapy
[4]. Furthermore, improvements in overall survival for
childhood AML over the past 30 years can be largely
attributed to more intensive use of conventional cytotoxics
and improved supportive care [5]. Conventional therapy for
pediatric AML parallels strategies that have been used in
adults and is based on intensive use of cytarabine (cytosine
www.oncotarget.com
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solid cancer types including AML, acute lymphoblastic
leukemia (ALL), breast, melanoma and prostate cancer
[11]. Inappropriate or prolonged activation of the Ras/
Raf/MEK/ERK1/2 pathway have been suspected to lead
to altered gene expression and contribute to cancer and
chemotherapy resistance [12]. Therefore, small molecule
inhibition of kinases within the pathway, such as MEK, has
been investigated for their therapeutic potential [13, 14].
Several MEK inhibitors have shown promising
pre-clinical activity in adult AML, with a number of
compounds currently being evaluated in phase I/II clinical
trials, including MEK162, GSK1120212 and AS703026
[15–19]. However, the frequent development of resistance
to kinase inhibitors, such as imatinib and sorafenib,
through a variety of mechanisms such as acquisition of
additional mutations within the kinase domains of the
target proteins, leads us to an important question: will
MEK inhibitor utility in AML be limited by rapid selection
and expansion of subclones that either express or develop
intrinsically resistant mutations in the pathway or that lack
dependence on MEK signaling for growth and survival?
To answer this question, we established an in vitro model
of MEK inhibitor resistance using THP-1 cells, incubated
in increasing concentrations of selumetinib (clinical trial
NCT00588809; completed), to identify the mechanism (s)
that may lead to resistance in AML patients. We identified a
partial deletion of the tumour suppressor phosphatase and
tensin homolog (PTEN) as a clinically relevant genomic
alteration in 100% of replicate resistance cell lines that
we developed. We also confirmed that disruption of the
PTEN catalytic core motif domain was the mechanism of
resistance using CRISPR-mediated deletion of PTEN exon
5, a region which contributes to the catalytic activity of
this tumour suppressor [20]. Given the observation that
PTEN deletion is a mechanism for MEKi resistance in
solid tumours [21, 22], and that deletion of PTEN in AML
is sufficient to confer resistance, we propose that this event
can be used as a biomarker of MEK inhibitor resistance in
AML. This is also the first report of PTEN deletion as a
mechanism of small molecule inhibitor resistance in AML.

assay. However, the majority exhibited nanomolar IC50s
across most cell lines (Table 1). Interestingly, one pediatric
AML cell line CMK and one adult AML cell line HEL
showed overt resistance to MEK inhibitors suggesting an
intrinsic resistance that does not require drug exposure or
selection pressure to develop.
Previous studies have shown that the MEKi
PD0325901 can inhibit cell cycle progression in the OCIAML3 cell line [23] and GSK1120212 induces cytostatic,
rather than cytotoxic, effects in particular cytogenetic
backgrounds in a variety of cancer cell lines [16]. Therefore,
it is possible that MEKi-associated anti-proliferative effects
observed in Table 1 are a consequence of MEKi-induced
cell cycle arrest. To test this hypothesis, we interrogated cell
cycles in the AML cells after a 96 h treatment with MEKi
(0.01, 0.1, 1 µM) (Supplementary Figure 1). We observed a
range of cell cycle responses, with most cell lines exhibiting
reduced S/G2/M populations in response to MEKi.

MEKi synergize with chemotherapeutic
compounds
The basis for poor clinical response in AML patients
is attributed to the development of resistance to current
chemotherapeutic protocols. One mechanism of resistance is
thought to be due to hyperactivation of the MAPK signalling
pathway owing to the production of reactive oxygen
species, a by-product of chemotherapy [11]. Therefore, we
hypothesized that inhibition of MAPK signalling in addition
to treatment with chemotherapy would sensitize cells to
death and potentially prevent the development of resistance.
To investigate the potential for synergistic therapeutic effect
between MEKi and the chemotherapeutic compounds
Ara-C, etoposide and daunorubicin, four pediatric AML
cell lines were co-treated for 96 h at fixed drug ratios (Table
2). The combination index (CI; quantitative measure of the
extent of drug interaction) was calculated for the ED50
(effective dose) using Chou-Talalay analysis [24]. AZD6244
was the most synergistic when combined with all cytotoxics
examined across all four cell lines with ED50 CI of <0.010.96. Combinations with other MEKi were variable (Table
2). However, it appeared that etoposide in combination with
MEKi trended towards antagonism (>1.1). Interestingly,
co-treatment of CMK cells (which are overtly resistant to
MEKi monotherapy) with either cytarabine or daunorubicin
sensitized the cells to the inhibition of proliferation. These
data suggest that combination therapy of MEKi with
cytotoxics that are currently in use clinically for pediatric
AML is a potential strategy to sensitize AML cells to growth
inhibition and cell death, even in the cells that are resistant
to MEKi monotherapy.

RESULTS
MEK inhibitors reduce proliferation in AML
cells in vitro
There is a considerable amount of in vitro, in vivo
and clinical data investigating the utility of MEK inhibitors
to treat adult AML [13, 14]. However, it is not known if
MEK inhibitors are efficacious in treating pediatric AML.
Therefore, we firstly interrogated whether pediatric AMLderived cell lines were sensitive to MEK inhibitors in
vitro. We used a panel of seven MEK inhibitors and tested
them in 11 cell lines including six pediatric and five adult
AMLs encompassing the most prevalent cytogenetic and
molecular features found in patients. We found varying
sensitivity across all compounds tested in a proliferation
www.oncotarget.com

Acquired PTEN haploinsufficiency contributes to
MEKi resistance
Resistance to small molecule inhibitors is a
recognized clinical problem across a range of cancers.
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Table 1: MEK inhibition reduces the proliferation of AML cells
Pedatric Cell line

Adult

Cytogenetics

Sequence Features

PD0325901 AZD6244 MEK162 GSK1120212 CI1040 TAK733 AS703026 Ara-C Daunorubicin Etoposide

MV-4-11

MLL-AF4

FLT3-ITD

0.17**

0.41*

0.33**

0.003***

6.9

0.089** 0.41**

1.6

0.048

0.056

THP-1

MLL-AF9

TP53(R174fs*3), NRAS 0.19***
(G12D)

0.3**

0.43**

0.08***

2.2*

0.23*** 0.23***

6.7

0.122

1.9

CMK

Myeloid
leukaemia
associated
with Down
Syndrome.
Complex

TP53(D49H and
M133K), CDKN2A
(M1_*157del),
JAK3 (A572V),
GATA1(E2fs*37)

>20

>20

>20

>20

>20

>20

>20

0.48

0.076

4.5

AML-193

Complex
NRAS (G13V)
karyotype with
4% polyploidy

0.24*

2.9

2.1

0.14*

4.8

0.25*

0.42*

2.6

0.057

3.4

Kasumi-1

t (8;21)(q22;
q22)

RUNX1-CBFA2T1;
c-KIT mut (N822K),
TP53 (R248Q)

0.2

1.7

1.1

0 004

6.5

0.051

0.31

0.15

0.028

0.53

M-07e

t (11;21)(p11;
p13)

CREBBP (Q2208H)

0.11

1.1

0.34

0.006

4.8

0.038

0.08

0.033

0.0069

0.18

ME1

CBFB-MYH11

0.003

0.022

0.037

0.00004

0.55

0.005

0.08

0.41

0.36

18

HL-60

MLL-AF6

0.12

0.02

0.001

0.73

0.001

0.007

0.64

0.02

1.3

ML-2

KMT2A-AFDN CREBBP (L1090*)
0.004
NOTCH1(P2514fs*4),
KRAS (A146T),
CDKN2A (M1*157del)

0.066

0.047

0.001

0.68

0.01

0.02

0.069

0.011

0.16

HEL

Hypertriploid
with 2.3%
polyploidy

JAK2 (V617F), TP53
(M133K), CDKN2A
(M1_*157del)

>20

>20

>20

>20

>20

>20

>20

0.085

0.12

1.6

OCI-AML3

Hyperdiploid
(+1, +5, +8,
der (1) t(1;18)
(p11; q11), i
(5p), del (13)
(q13q21), dup
(17)(q21q25))

DNMT3A (R882C),
NPM1 (W288fs*12)

0.008

0.07

0.04

9.20E-05

1.1

0.004

0.02

>20

0.019

0.47

0.11

0.3

0.33

0.003

2.2

0.038

0.08

0.445

0.048

1.3

Median
all

CDKN2A (R80* and 0.001
P135L), NRAS (Q61L),
t (6,11)(q27; q23)

IC50 is defined as the concentration of drug that reduces cell viability by 50%, calculated by non-linear regression. Median all is calculated excluding those values >20 uM where an exact
IC50 could not be established.

It has become evident that surveillance for resistance
is imperative to detect early relapse in patients and
understanding the mechanisms and biomarkers for
resistance is key. Therefore, we developed eight THP-1
cell lines independently derived to have resistance against
AZD6244, subsequently referred to as TR, to investigate
the how cells acquire resistance to MEKi.
We hypothesized that TR cells acquired somatic
mutations in MEK-related genes which contribute to
MEKi resistance [25]. In order to characterize these
acquired mutations, we performed targeted exome
sequencing on THP-1 cells grown in culture with DMSO
only (control) (n=8) and on the TR (n=8) cells. A total
of 239 single nucleotide variants (SNVs) were identified
(Supplementary File 1). However, no SNVs were recurrent
across all resistant lines suggesting they were not the
drivers of resistance. The most commonly occurring SNV
was a missense mutation in NTRK2 (chr9:87570296, in 4
of 8 resistant lines) (Supplementary Figure 2). However,
the low variant allele frequencies (range: 12%-19%)
suggest that this mutation is likely subclonal and does not
contribute significantly to MEKi resistance. In contrast
to small number of SNVs, copy number changes were
www.oncotarget.com

found in 835 genes including a single, clonal copy loss of
PTEN in all 8 resistant samples (Supplementary File 2).
We also observed subclonal copy gain of KRAS in all 8
samples, as well as subclonal copy loss of both ELOVL2
and IRF4 (Figure 1), all of which have been identified
in tumours although the effect of these copy number
losses in AML is unknown. Interestingly, PTEN exons
appeared to be affected differently. For example, exon 2
appeared to be unaffected in the resistant lines, whereas
exons 5 to 9, which encode the motif contributing to the
catalytic phosphatase activity of PTEN [20], seemed to be
consistently lost.
To interrogate the functional impact of the deletion
of large regions of PTEN as observed in the TR cells, we
investigated whether genomic copy losses were reflected
in transcriptional levels. Due to the importance of exons
5, 8 and 9 in the function and stability of PTEN, we
quantified the expression of these regions, as well as the
region encompassing exons 1 and 2, which was unaffected
in resistance cells, as a control. Our results showed that
the exons 1 and 2 had similar transcriptional levels across
TR, control and parental (THP-1) lines, while we observed
a significant decrease in the expression of the exons 5, 8
5757
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Table 2: Combination index between MEK inhibitors and conventional chemotherapeutic compounds
Cell line
Drug A
Drug B
Combination index
+++
Cytarabine
0.34
+++
AS703026
Daunorubicin
0.31
Etoposide
>1.1
+++
Cytarabine
0.49
CMK
+++
AZD6244
Daunorubicin
<0.01
+++
Etoposide
0.6
+++
Cytarabine
0.32
+++
GSK1120212
Daunorubicin
0.14
Etoposide
>1.1
Cytarabine
>1.1
AS703026
Daunorubicin
>1.1
Etoposide
>1.1
+++
Cytarabine
0.24
Kasumi1
AZD6244
Daunorubicin
0.96
±
+++
Etoposide
0.24
Cytarabine
>1.1
GSK1120212
Daunorubicin
>1.1
Etoposide
>1.1
++
Cytarabine
0.85
AS703026
Daunorubicin
0.95
±
Etoposide
1.1
±
+++
Cytarabine
0.42
MV-4-11
+++
AZD6244
Daunorubicin
0.47
+++
Etoposide
0.52
Cytarabine
>1.1
++
GSK1120212
Daunorubicin
0.82
Etoposide
>1.1
+++
Cytarabine
0.64
+++
AS703026
Daunorubicin
0.67
Etoposide
>1.1
+++
Cytarabine
0.36
THP-1
+++
AZD6244
Daunorubicin
0.43
+++
Etoposide
0.51
Cytarabine
>1.1
GSK1120212
Daunorubicin
>1.1
Etoposide
>1.1
Combination index was calculated from the ED50 using Chou-Talalay analysis in the CalcuSyn software; -, antagonism
(>1.1); ±, additive (0.9–1.1); ++, moderate synergism (0.7–0.9); +++, synergism (0.3–0.7).

Introduction of truncated PTEN in parental
THP-1 cells results in MEK inhibitor resistance

and 9 in the TR cells (Figure 2B). Moreover, PTEN levels,
measured by immunoblot with an antibody specific to the
C-terminal epitope, paralleled our qPCR results where
PTEN levels were barely detected in the resistant cells,
but were consistent and detectable in both parental cells
and control cells (Figure 2C). These results show that the
alterations in PTEN were perpetuated at both the transcript
and protein levels.
www.oncotarget.com

Although PTEN loss has been suggested to play a
role in drug resistance, there has not been any evidence
to show the direct link between PTEN loss and drug
resistance, particularly in AML, to our knowledge. To
investigate whether loss of functional PTEN directly
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contributes to resistance to MEKi, we used CRISPR/
Cas9 technology to introduce the functional loss of
PTEN that we observed in resistance cells into parental
(and therefore MEKi-sensitive) THP-1 cells. Using a
ribonuclear protein (RNP) complex comprised of each of
3 gRNAs that targets the exon 5 of PTEN (gP1, gP2, gP3),
a fluorophore-labelled scaffolding RNA (tracrRNA) and a
recombinant Cas9 protein, we introduced mutations at the
locus that encodes the exon 5 of PTEN. These mutations
resulted in a frameshift in the translation of the protein,
as described previously [26], resulting in abrogation
of the core catalytic motif in PTEN (Supplementary
Figure 3A). An RNP complex using a gRNA that targets
a gene desert region (gN) was included as a control for
CRISPR. The 3 PTEN-targeting gRNAs were tested using
a T7 endonuclease I assay, and all were proven to be able
to introduce mutations into the designated locus in cells
named P1, P2, P3 (Supplementary Figure 3B, 3C). Cells

CRISPRed with gN (N) did not show any specific cleavage
at this locus (Supplementary Figure 3C). Interestingly,
CRISPRed cells (P1, P2, P3 and N) were viable when we
expanded each of them 24 h post transfection in culture to
a density of 106 cells/ml. Further T7 endonuclease I assays
on P1, P2, P3, N and THP-1 cells revealed that mutations
at the PTEN locus were retained, and THP-1 and N cells
were not digested by T7, indicating that N cells share
the same genomic sequence as the parental cells at the
exon 5 of PTEN (Figure 3A). These results were further
supported by Western blots, where THP-1 and N cells
had comparable levels of PTEN (Figure 3B). In contrast,
PTEN was undetectable in P1, P2 and P3 cells, and in a
previously established resistant line (TR) (Figure 3B). We
then measured IC50 of P1, P2, P3, and N cells, along with
the THP-1 cells and TR cells, in the presence of AZD6244.
We found that the N cells had a similar IC50 to THP-1 cells
(IC50~0.2 uM) while P1, P2, and P3 all had IC50s similar to

Figure 1: Copy number changes acquired during generation of MEKi-resistant phenotype. Copy number variation analysis

of all TR populations revealed amplification and deletion events common to all samples which are known to be associated with cancer and/
or drug resistance. These events include deletion of PTEN, IRF4, and ELOLV2 and amplification of KRAS. TR copy changes are shown
relative to DMSO controls. Each panel describes copy changes for the chromosome indicated in the title bar. Circle size indicates the
statistical significance of the difference in gene copies (Bonferroni-adjusted p-values); large circles represent p < 0.001, medium circles
represent 0.001 < p < 0.05; and small circles represent p ≥ 0.05. Circle colour represents replicates.
www.oncotarget.com

5759

Oncotarget

Figure 2: PTEN loss in TR cells. (A) Copy number changes of PTEN exons. Normalized depth (log) of each probe targeting PTEN

(indicated by o and •) was obtained by targeted exome sequencing. Grey line indicates the average depth of the entire locus. Dots above
and below the grey line indicate gain and loss in copy numbers, respectively, at the targeted locus. (B) qPCR analysis of PTEN expression.
The transcriptional levels of the exon 1–2, exon 5 and exon 8–9 of PTEN were determined by qPCR and normalized to GUSB. (C)
Representative western blot of PTEN levels in the parental cells (lane 1), control cells (2–5) and resistant cells (6-9). GAPDH (37 kD) was
used as a loading control for each blot. Data are presented as mean and standard deviation. **p < 0.01 (t-test, two-tailed).
www.oncotarget.com
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TR cells (IC50 >20 uM) (Figure 3C). These results showed
that the off-target effect of CRISPR had minimal impact
on THP-1 sensitivity to AZD6244, and, for the first time,
shows the direct contribution of functional PTEN loss to
the establishment of MEKi resistance.

phosphorylation of CREB at Ser133, which may promote
MEKi resistance as previously reported (Figure 3D) [28].

DISCUSSION
An improved treatment strategy is desperately
needed for pediatric AML due to the side effects of current
chemotherapy regimens. The Ras/Raf/MEK/ERK1/2
pathway plays an essential role in human cancers and
its contribution in leukemogenesis has been supported
by a high incidence of mutations identified in the RAS
gene family, such as NRAS [29–31] and by inappropriate
activation of the pathway. MEK inhibitors are small
molecules that have shown promise in clinical trials.
However, little is known about their therapeutic potential
in treating pediatric AML or whether mutations in RAS
gene family could predict sensitivity to MEK inhibitors.
Therefore, we used seven MEK inhibitors that have been
investigated in clinical trials and examined their efficacy
against a panel of 11 AML cell lines, six of which were
pediatric (Table 1).
Our data demonstrate that this response to MEK
inhibitors is independent of RAS mutational status. THP1 cells (NRASG12D) exhibited nanomolar IC50s for six of
the seven MEKi. In contrast, AML-193 cells (NRASG13V)
exhibited nanomolar sensitivity to just four of the seven

PTEN loss correlates with an increase in
transcription and activation of CREB
It has reported that CREB is a direct target of
PTEN where PTEN physically interacts with, and
dephosphorylates CREB at Serine 133 [27]. Interestingly,
cancerous cells have been shown to restore the CREB
phosphorylation that is suppressed upon MEK inhibitor
treatment [28]. Therefore, we speculated that loss
of the functional domain of PTEN increases CREB
phosphorylation (pCREB) in leukemic cells, thus
promoting cell survival and MEKi resistance. To test this
hypothesis, we measured the total CREB (tCREB) levels
and pCREB levels (S133) in TR, control and parental
(THP-1) cells. Our results showed that parental cells
and control cells had comparably low levels of tCREB
and pCREB, while resistant cells showed elevated levels
of both tCREB and pCREB (Supplementary Figure 4).
This result suggests that loss of the functional domains
of PTEN, at least in part, gives rise to an increased

Figure 3: Truncated PTEN is associated with resistance to MEKi via increased activity of CREB. (A) T7 endonuclease I

assay of the CRISPRed THP-1 lines (P1, P2, P3 and N). (B) Representative Western blot of PTEN (54 kD) in each of the CRISPRed lines
(N, P1, P2, P3), parental THP-1 cells and TR cells. GAPDH (37 kD) was used as a loading control. (C) Sensitivity of CRISPRed lines to
AZD6244. Four independent experiments were performed and the mean of each sample at a given AZD6244 concentration was plotted.
(D) Representative Western blot of pCREB and tCREB in the parental cells, control cells (1–4) and resistant cells (5–8). GAPDH (37 kD)
was used as a loading control for each blot.
www.oncotarget.com
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MEKi. However, other cell lines such as MV-4-11 and
OCI-AML3 that do not express a RAS mutation exhibit
nanomolar IC50 values in six of the seven MEKi. This
resistance may be explained by other oncogenic events
in AML that drive Ras pathway activation such as FLT3ITD mutations. Indeed, MV-4-11 possesses this mutation.
This observation has been supported by extensive clinical
studies in solid tumours such as melanoma where the
presence of Ras/Raf mutations did not elicit a uniform
response and the variations were considered to be a result
of co-occurring mutations [32, 33]. A recent study with
AZD6244 in AML, however, showed that no patient with
FLT3-ITD responded to treatment, whilst 17% of FLT3WT patients exhibited a response [13]. Taken together,
these data indicate that the sensitivity to MEKi is not
likely to be easily stratified according to a single mutation,
including Ras or Raf mutations.
Interestingly, two cell lines (CMK and HEL)
exhibited overt intrinsic resistance to MEKi with IC50
above 20 µM (Table 1). These cell lines share the common
element of a mutation in the JAK/STAT pathway and a
p53M133K mutation. CMK cells express a JAK3A572V
mutation and HEL express the well-characterized
JAK2V617F mutation. Whilst numerous reports suggest
activation of the PI3K/AKT pathway may elicit resistance
to MEKi due to the nature of cross-talk between these two
signaling pathways [34], the role of JAK/STAT pathway
activation has not been extensively explored. Future
studies investigating the functional influence of JAK/STAT
signaling on MEKi sensitivity may have an important
clinical impact for classifying patients who are unlikely
to respond to MEKi monotherapy, or those where addition
of a JAK inhibitor, such as ruxolitinib or pacritinib, may
prove beneficial.
Despite the maintenance of a common structural
backbone in all MEK inhibitors, a range of antiproliferative efficacy was observed, suggesting that a
subset of AML cells are likely to require co-treatment
with a second compound to induce complete population
death. This hypothesis has been supported by in
vitro studies and clinical trials of MEKi [35, 36]. We
showed that combinations of MEKi with the cytotoxic
agents, cytarabine and daunorubicin - currently used
in chemotherapy, appeared to be overall synergistic.
However, combinations with etoposide varied depending
on the MEKi and the cell line (Table 2). It should be noted
that all past and current clinical trials investigating the
use of MEKi in AML have been in adults and, as such,
the preclinical data presented here provide a rationale for
investigating the use of chemotherapy supplemented with
MEKi in pediatric AML patients.
Increasing amounts of effort have been spent on
exploring how cancer cells acquire resistance to MEK
inhibitors. We attempted to investigate the genetic
attributes of MEKi resistance. After establishment of
MEKi resistance in independent populations of an AML
www.oncotarget.com

cell line we observed only one universally occurring
mutation – copy loss of a functional domain in PTEN
(Figure 1). No other acquired point mutations or copy
changes (Supplementary File 2) in the targeted exome
panel were observed in all resistant replicates compared
to the control replicates. This mutation appeared to be
clonally dominant suggesting that it was able to confer a
significant survival advantage on these cells while being
challenged with a MEKi and also that it likely occurred
prior to the other acquired mutations that we observed.
Furthermore, we were able to demonstrate that abrogation
of PTEN function by introducing what is effectively the
same acquired mutation into the parental, MEKi-sensitive
cell line was sufficient to confer MEKi resistance in these
cells. It is possible that other mutations were universally
acquired in the resistant replicates in other regions of
the genome as we interrogated only the genes present
in the targeted exome panel. However, the evidence that
the single CRISPRed PTEN mutation was able to confer
the same level of acquired MEKi resistance on the parental
cells is highly suggestive that this single event is sufficient
for resistance given the genetic background of this AML
cell line. Similarly, when we treated these cells with other
MEKi, we again observed a lack of sensitivity to these
agents suggesting that there is a common mechanism of
resistance (Table 3). Interestingly, PTEN loss is associated
with resistance to MEK inhibitors in a variety of cancers,
and in fact may be a common mechanism for conferring
resistance to other therapies such as PI3Kβ and BRAF
inhibitors and immunotherapy [21, 22, 37–39].
In addition to PTEN loss, we observed some
additional universal copy changes (Figure 1). Because
these copy change events appear to be present in a smaller
proportion of cells than the PTEN loss we believe these
changes occurred subsequent to the PTEN event and may
be secondary to acquired MEKi resistance. For example,
we observed amplification of KRAS. While the role of
mutated KRAS in cancer and therapy resistance has been
widely described, KRAS gene amplification appears to
be associated with tumour phenotype rather than with
the acquisition of therapy resistance [40]. Loss of IRF4,
an event we observed in all of our resistant replicates, is
reported to be associated with leukemic progression in
both lymphoid and myeloid cells, which is consistent with
the tumour suppression function of this protein [41–43].
Finally, we observed universal loss of ELOVL2 in our
resistant replicates. While this gene has been implicated
in cancer [44, 46] it is unclear what role this event may
play in either leukemia or therapy resistance.
Interestingly, three resistant replicates acquired a
single nucleotide variant in NTRK2 at the same position
(chr9:87570296) potentially causing a G>D substitution
at amino acid 679 in the protein (Supplementary Figure
2). This mutation has not been previously reported so
it is unclear what affect, if any, it may have on protein
function. One study found that NTRK2 activation
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Table 3: MEK inhibitor resistance in THP-1 AML cells
Cell line
AZD6244
MEK162
GSK1120212
AS703026
Parental
0.3
0.43
0.08
0.23
TR
>20
>20
>20
>20
Values shown are IC50s, defined as the concentration of drug that reduces cE by non-linear regression. Values >20 uM
indicate where an exact IC50 coulc Ara-C; cytarabine arabinoside.
cooperates with PTEN loss in T-ALL [45, 47] so it is
tantalizing to hypothesize that this mutation acts in a
similar way in these cells providing them with yet another
survival advantage. Indeed, the observed variant is only
three residues from the active site of this enzyme and is
proximal to autophosphorylated tyrosine residues (based
on a mapping of UniProt entry Q16620 to protein structure
1WWB.X) [39].
While PTEN loss has been previously implicated in
resistance to a number of other therapeutic agents, this is
the first time that it has been shown directly and in AML.
We were also able to demonstrate that MEKi synergize
with other chemotherapeutic compounds, at least in some
cases, so, while MEKi utility in AML is clearly limited
by the development of resistant subclones, combination
therapy may be a viable strategy to mitigate this effect.
In addition, establishment of PTEN status at diagnosis,
as well as the status of other events known to contribute
to MEK signaling-independent growth (e. g., FLT3ITD) may identify patients that are unlikely to respond
to MEKi therapy and thus inform alternative treatment
approaches.

MATERIALS AND METHODS

The concentration of compound that reduced cell viability
by 50% (IC50) was determined using non-linear regression
with variable slope after normalising fluorescence to
untreated cellular controls. For combination assays, cells
were treated with fixed ratio concentrations of one MEKi
(GSK1120212, AS703026 or AZD6244) in combination
with one cytotoxic compound (cytarabine, daunorubicin
or etoposide) for 96 h. For cell cycle analysis, cells (2 ×105
cells/mL) were seeded in 96-well plates with appropriate
factors and the indicated compound concentrations for 96
h. Assayed cells were fixed in 100 µL 70% ethanol in
PBS at 4° C. Cells were washed in PBS then incubated
with 40 mg/mL propidium iodide (PI; Sigma Aldrich,
MO, USA) and 250 mg/mL RNase (Sigma Aldrich) for
30 minutes at 37° C. Apoptosis was measured using the
annexin-V FITC apoptosis detection kit according to
manufacturer’s instructions (BD Biosciences). AML cell
lines were seeded at 2 × 105 cells/mL and treated with
indicated concentrations of compound for 96 h. Samples
were stained for annexin-V FITC (BioLegend, CA, USA)
and PI. Samples were analyzed on an LSRII FortessaTM
flow cytometer (BD Biosciences, NJ, USA), data were
acquired using the BD FACSDiva software and analysed
with FlowJo software.

Cell culture and reagents

Immunoblotting

All human AML cell lines were purchased directly
from recognized repositories; Kasumi-1, MV-4-11, CMK,
AML-193, M-07e, HL-60, ML-2, OCI-AML3, ME-1 and
HEL from DSMZ (Braunschweig, Germany) and THP-1
from ATCC (Manassas, USA).
AZD6244, PD0325901, GSK1120212, CI-1040,
TAK-733, AS703026, MEK162, cytarabine (cytosine
arabinoside), daunorubicin hydrochloride (daunorubicin)
and etoposide were obtained from Selleck chemicals
(Houston, USA). ARRY-162 was purchased from
ChemieTek (Indiana, USA). All compounds were
dissolved in DMSO and stored at –20° C.

Cells were washed and lysed as previously described
[23]. Total protein (10µg) was separated by SDS-PAGE
and transferred onto nitrocellulose membranes (GE
Healthcare, Buckinghamshire, England). Antibodies used
for immunoblotting included anti-pMEK1/2(Ser217/221),
-MEK1/2 total, -ERK1/2(Thr202/Tyr204), -ERK1/2 total,
PARP, -pAKT (S473), -AKT, pCREB (S133) and CREB
(Cell Signalling Technology, Inc., MA, USA) and antiGAPDH (Millipore, USA). Membranes were incubated
with IRDye® 680LT or IRDye 800CW conjugated
secondary antibodies and protein-antibody complexes
visualized as previously described [48].

Cell proliferation, cell cycle and apoptosis assays

Development of MEKi-resistant THP-1 cells

Human AML cell lines (2 × 104 cells/well) were
seeded in a 96-well plate with appropriate factors and
the indicated concentrations of compound for 96 hours.
Assays were plated in quadruplicate and repeated at least
three times. Proliferation was assessed using a resazurin
reduction assay (CellTiter-Blue™, Promega, WI, USA).

THP-1 cells with resistance to AZD6244 (referred
to as TR) were developed by culturing THP-1 cells in the
presence of increasing concentrations of the compound
(with ≤0.1% DMSO) until confluent growth was sustained
in 20 times the IC50 (>10 µM). Resistance was confirmed
by incubating cells in drug free media for a minimum of
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one week followed by CTB assay with drug concentrations
up to 20 µM. Subsequent experiments using the TR lines
were carried out on cells incubated in drug free media for
a minimum of one week. The resistance development was
replicated 8 independent times and paired with DMSO
treated controls to establish background mutation rate
occurring over time with culture.

CRISPR was performed using Ribonuclear protein
(RNP) complex system to introduce mutations in the
exon 5 of PTEN, which encodes the catalytic core motif
of the protein [20]. Guide RNAs (gRNAs) were designed
using a web designing tool (http://portals.broadinstitute.
org/gpp/public/analysis-tools/sgrna-design). A total of 3
gRNAs (gP1, gP2, gP3) that target the bases before the
core motif-encoding region were selected based on their
target efficiency score (Supplementary Table 2). Each
of the 3 gRNAs was then complexed with an ATTO550 labelled scaffolding RNA (tracrRNA) (IDT, USA)
and a recombinant Cas9 protein (NEB, USA) following
manufacturer’s instructions. The RNP complexes (10nM)
were transfected into THP-1 cells using RNAiMax (Life
Technologies, USA); and the cells were cultured at 37° C
with 5% CO2. A CRISPR experiment using a negative
control gRNA (N) (IDT, USA) was also performed
along with other CRISPR experiments. Genome editing
efficiency was measured 48 h post-transfection.

Exome sequencing
Libraries were prepared using the Nugen Ovation
Target Enrichment System and 2 × 150 bp paired end
sequencing was performed on the Illumina MiSeq v2
at the Monash Health Translation Precinct Medical
Genomics Facility. The Ovation Cancer Panel 2.0 Target
Enrichment Probes panel was used to perform targeted
exome sequencing of known cancer genes to mean
depth of coverage of 53× (range 47–67×) according to
manufacturer’s specifications. Briefly, 500ng of DNA from
8 resistant cell lines and the paired DMSO controls was
sheared, ligated to adapter probe and purified. Libraries
were pooled for enrichment at equimolar ratios and 15 pM
of a single pool was used for clustering. The total run
yield was 4.3G encompassing a total of 14,319,766 reads.
The 1% PhiX spike in parameters were rated excellent
for having an error rate of 0.27% and phasing/prephasing
of 0.092/0.051. Reads were aligned to the hs37d5 human
reference genome using NovoAlign followed by duplicate
read marking and base quality recalibration according to
GATK best practices. Single nucleotide variants and small
indels were called using mutect2 [49]. To investigate copy
number variation, bedtools 2.26.0(CITE: https://academic.
oup.com/bioinformatics/article/26/6/841/244688/BEDToolsa-flexible-suite-of-utilities-for) was used to calculate mean
coverage depth per exon in each sample. Exons with group
mean coverage below 20 reads in both control and treated
groups were excluded from the analyses to reduce noise.
Read depths in each sample were normalized by total library
size, and control and treated normalized exon read depths
compared using a Student’s t-test (p-values adjusted using
the Bonferroni correction) to identify alterations in copy
number.

Measurement of genome-editing efficiency
Genome editing efficiency was measured using
T7 endonuclease I according to the manufacturer’s
instructions (NEB, USA). Briefly, genomic DNA (gDNA)
was extracted using Genomic DNA isolation kit (Bioline,
USA). A pair of primers were used in the presence of
the Platinum Taq DNA Polymerase High Fidelity (Life
Technologies, USA) to amplify a 595 bp region including
357 bp of the intron 4 that is sitting immediately upstream
of the exon 5 and 238 bp of the exon 5 from 200ng of
gDNA (Supplementary Table 1). Cycling was performed
using Eppendorff PCR thermocycler for a total of 35
cycles. Each cycle started with denaturing at 94° C for
15s, followed by annealing at 60° C for 30s and an
extension at 68° C for 30s. The PCR products were then
ramped following the manufacturer’s instruction (IDT,
USA) and digested using 10 units of T7 endonuclease I
at 37° C for 15 min. Fragmentation was separated by gel
electrophoresis and visualized by Quantum ST4 Xpress
system (Montreal Biotech, USA).

qPCR validation of PTEN loss by transcription
quantification
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